QNRX
Quoin Pharmaceuticals Ltd DRCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$11.69M
P/E Ratio
—
EPS
$-14.80
Beta
1.82
52W High
$23.50
52W Low
$5.20
50-Day MA
$7.31
200-Day MA
$9.80
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals Ltd (QNRX) is a biotechnology company dedicated to developing innovative therapeutics targeting rare diseases and unmet medical needs. Leveraging advanced drug delivery technologies, Quoin aims to improve the efficacy and safety of existing compounds, thereby strengthening its foothold in the specialty pharmaceuticals landscape. The company's promising pipeline features therapies addressing critical health conditions, offering potential for significant clinical advancements and commercial opportunities. Committed to delivering value for patients and investors alike, Quoin actively pursues strategic collaborations and pioneering research initiatives.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-16.19M |
| Operating Margin | 0.00% |
| Return on Equity | -141.60% |
| Return on Assets | -56.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $8.76 |
| Price-to-Book | 0.89 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $1.80M |
| Float | $50.45M |
| % Insiders | 2.93% |
| % Institutions | 50.09% |
Historical Volatility
HV 10-Day
78.57%
HV 20-Day
90.44%
HV 30-Day
120.37%
HV 60-Day
96.44%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($29.67 target)
1
Strong Buy1
BuyData last updated: 5/1/2026